Related Experiment Video
Updated: Oct 7, 2026
Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics
Published on: February 19, 2017
Update: newborn screening for sickle cell disease--California, Illinois, and New York, 1998
Insights
Newborn screening for sickle cell disease (SCD) is crucial for early intervention. However, this study found challenges in tracking screened children to evaluate program effectiveness.
Area of Science:
- Genetics
- Pediatrics
- Public Health
Background:
- Sickle cell disease (SCD) is a prevalent single-gene disorder affecting Black newborns, posing significant health risks including anemia, infections, and mortality.
- Children with SCD face heightened risks for severe morbidity and mortality, particularly within the first three years of life.
- Universal newborn screening for hemoglobinopathies is available in key states like California, Illinois, and New York.
Purpose of the Study:
- To evaluate the effectiveness of newborn screening programs for sickle cell disease.
- To assess the receipt and compliance of early medical interventions, such as penicillin prophylaxis and vaccinations, for infants diagnosed with SCD.
- To identify challenges in retrospectively assessing program effectiveness due to difficulties in tracking screened children.
Main Methods:
- A 3-year collaborative follow-up study was conducted from 1995 to 1998.
- The study focused on California, Illinois, and New York, states with universal newborn screening for hemoglobinopathies.
- Data collection aimed to assess screening effectiveness and intervention compliance, but faced retrospective tracking challenges.
Main Results:
- The study highlighted significant difficulties in retrospectively identifying children who underwent newborn screening for SCD.
- Challenges in data retrieval and patient tracking hindered a comprehensive evaluation of program effectiveness.
- This underscores the need for improved systems for monitoring and evaluating newborn screening programs.
Conclusions:
- Effective newborn screening for sickle cell disease is essential for early intervention and improved outcomes.
- Retrospective assessment of screening program effectiveness is hampered by difficulties in tracking patients.
- Further development of robust follow-up mechanisms is necessary to accurately evaluate public health interventions for SCD.
Abstract:
Sickle cell disease (SCD) is a common single-gene disorder that affects three of every 1000 black newborns and approximately 50,000 persons in the United States. Children affected with SCD are at increased risk for severe morbidity (e.g., severe hemolytic anemia, splenic dysfunction, pain crises, and bacterial infections) and mortality, especially during the first 3 years of life. In 1993, California, Illinois, and New York collectively accounted for approximately 20% of all births to blacks. All three states offer universal newborn screening for hemoglobinopathies. To assess the effectiveness of newborn screening programs for SCD and for receipt of and compliance with early medical interventions (e.g., penicillin prophylaxis and pneumococcal vaccination and other vaccination patterns), a 3-year collaborative follow-up study was conducted from 1995 through 1998 in California, Illinois, and New York. This report summarizes the results of this study, which demonstrate the difficulty in retrospectively finding children who were screened at birth so that data for evaluating program effectiveness can be assessed.